Pilar Blancafort

List of Publications by Year
in descending order

64 papers	3,261 citations	136950 32 h-index	149698 56 g-index
65 all docs	65 docs citations	65 times ranked	4196 citing authors

#	Article	IF	Citations
1	A peptide-functionalised dendronised polymer for selective transfection in human liver cancer cells. New Journal of Chemistry, 2021, 45, 19315-19320.	2.8	1
2	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer. Nature Communications, 2021, 12, 1920.	12.8	19
3	Reprogramming the anti-tumor immune response via CRISPR genetic and epigenetic editing. Molecular Therapy - Methods and Clinical Development, 2021, 21, 592-606.	4.1	11
4	Design and Characterization of a Cell-Penetrating Peptide Derived from the SOX2 Transcription Factor. International Journal of Molecular Sciences, 2021, 22, 9354.	4.1	4
5	Manipulating the NKG2D Receptor-Ligand Axis Using CRISPR: Novel Technologies for Improved Host Immunity. Frontiers in Immunology, 2021, 12, 712722.	4.8	2
6	SP94-Targeted Nanoparticles Enhance the Efficacy of Sorafenib and Improve Liver Cancer Cell Discrimination. ACS Applied Bio Materials, 2021, 4, 1023-1029.	4.6	5
7	Precision medicine by designer interference peptides: applications in oncology and molecular therapeutics. Oncogene, 2020, 39, 1167-1184.	5.9	61
8	Epigenome engineering: new technologies for precision medicine. Nucleic Acids Research, 2020, 48, 12453-12482.	14.5	34
9	Honeybee venom and melittin suppress growth factor receptor activation in HER2-enriched and triple-negative breast cancer. Npj Precision Oncology, 2020, 4, 24.	5.4	86
10	Rab GTPases: Emerging Oncogenes and Tumor Suppressive Regulators for the Editing of Survival Pathways in Cancer. Cancers, 2020, 12, 259.	3.7	43
11	Innovative Precision Geneâ€Editing Tools in Personalized Cancer Medicine. Advanced Science, 2020, 7, 1902552.	11.2	9
12	Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene, 2019, 38, 140-150.	5.9	55
13	Triple-hit therapeutic approach for triple negative breast cancers using docetaxel nanoparticles, EN1-iPeps and RGD peptides. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 20, 102003.	3.3	36
14	Tumour suppression by targeted intravenous non-viral CRISPRa using dendritic polymers. Chemical Science, 2019, 10, 7718-7727.	7.4	37
15	Activating PTEN Tumor Suppressor Expression with the CRISPR/dCas9 System. Molecular Therapy - Nucleic Acids, 2019, 14, 287-300.	5.1	68
16	Hallmarks of cancer: The CRISPR generation. European Journal of Cancer, 2018, 93, 10-18.	2.8	54
17	Non-viral Methodology for Efficient Co-transfection. Methods in Molecular Biology, 2018, 1767, 241-254.	0.9	5
18	Zinc Fingers, TALEs, and CRISPR Systems: A Comparison of Tools for Epigenome Editing. Methods in Molecular Biology, 2018, 1767, 19-63.	0.9	73

#	Article	IF	Citations
19	Aurantoside C Targets and Induces Apoptosis in Triple Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 361.	4.6	19
20	Crambescidin 800, Isolated from the Marine Sponge Monanchora viridis, Induces Cell Cycle Arrest and Apoptosis in Triple-Negative Breast Cancer Cells. Marine Drugs, 2018, 16, 53.	4.6	30
21	Atomistic molecular dynamics simulations of bioactive engrailed 1 interference peptides (EN1-iPeps). Oncotarget, 2018, 9, 22383-22397.	1.8	9
22	Synthetically controlling dendrimer flexibility improves delivery of large plasmid DNA. Chemical Science, 2017, 8, 2923-2930.	7.4	101
23	Waking up dormant tumor suppressor genes with zinc fingers, TALEs and the CRISPR/dCas9 system. Oncotarget, 2016, 7, 60535-60554.	1.8	61
24	Re-expression of Selected Epigenetically Silenced Candidate Tumor Suppressor Genes in Cervical Cancer by TET2-directed Demethylation. Molecular Therapy, 2016, 24, 536-547.	8.2	33
25	Epigenome Engineering in Cancer: Fairytale or a Realistic Path to the Clinic?. Frontiers in Oncology, 2015, 5, 22.	2.8	63
26	Stable oncogenic silencing in vivo by programmable and targeted de novo DNA methylation in breast cancer. Oncogene, 2015, 34, 5427-5435.	5.9	71
27	Gene expression in breastmilk cells is associated with maternal and infant characteristics. Scientific Reports, 2015, 5, 12933.	3.3	77
28	Breastmilk Stem Cells: Recent Advances and Future Prospects. , 2015, , 185-195.		1
29	The CRISPR road: from bench to bedside on an RNA-guided path. Annals of Translational Medicine, 2015, 3, 174.	1.7	0
30	Long live the stem cell: The use of stem cells isolated from post mortem tissues for translational strategies. International Journal of Biochemistry and Cell Biology, 2014, 56, 74-81.	2.8	10
31	Analysis of an artificial zinc finger epigenetic modulator: widespread binding but limited regulation. Nucleic Acids Research, 2014, 42, 10856-10868.	14.5	56
32	Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene, 2014, 33, 4767-4777.	5.9	76
33	Systemic Delivery of Modified mRNA Encoding Herpes Simplex Virus 1 Thymidine Kinase for Targeted Cancer Gene Therapy. Molecular Therapy, 2013, 21, 358-367.	8.2	164
34	Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules. Molecular Pharmacology, 2013, 83, 563-576.	2.3	30
35	Breaking through an epigenetic wall. Epigenetics, 2013, 8, 164-176.	2.7	20
36	Cisplatin Induces Differentiation of Breast Cancer Cells. Frontiers in Oncology, 2013, 3, 134.	2.8	48

#	Article	IF	Citations
37	Expression of the Pluripotency Transcription Factor OCT4 in the Normal and Aberrant Mammary Gland. Frontiers in Oncology, 2013, 3, 79.	2.8	28
38	Breastmilk and the lactating breast as a tool to elucidate breast cancer. FASEB Journal, 2013, 27, 629.9.	0.5	0
39	Targeting Serous Epithelial Ovarian Cancer with Designer Zinc Finger Transcription Factors. Journal of Biological Chemistry, 2012, 287, 29873-29886.	3.4	38
40	Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Research, 2012, 40, 6725-6740.	14.5	138
41	Epigenetic reprogramming of cancer cells via targeted DNA methylation. Epigenetics, 2012, 7, 350-360.	2.7	189
42	Sequence-Specific Biosensors Report Drug-Induced Changes in Epigenetic Silencing in Living Cells. DNA and Cell Biology, 2012, 31, S-2-S-10.	1.9	15
43	Breastmilk Is a Novel Source of Stem Cells with Multilineage Differentiation Potential. Stem Cells, 2012, 30, 2164-2174.	3.2	215
44	Generation of tumor-initiating cells by exogenous delivery of OCT4transcription factor. Breast Cancer Research, 2011, 13, R94.	5.0	81
45	Engineering Transcription Factors in Breast Cancer Stem Cells. , 2011, , .		0
46	Suppression of Breast Tumor Growth and Metastasis by an Engineered Transcription Factor. PLoS ONE, 2011, 6, e24595.	2.5	45
47	Reactivation of<i>MASPIN</i>in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics, 2011, 6, 224-235.	2.7	42
48	G9aâ€induced epigenetic silencing of maspin in human claudinâ€low breast tumor initiating cells. FASEB Journal, 2011, 25, 122.6.	0.5	0
49	Remodeling Genomes with Artificial Transcription Factors (ATFs). Methods in Molecular Biology, 2010, 649, 163-182.	0.9	9
50	Modulation of drug resistance by artificial transcription factors. Molecular Cancer Therapeutics, 2008, 7, 688-697.	4.1	22
51	Rational Design, Selection and Specificity of Artificial Transcription Factors (ATFs): The Influence of Chromatin in Target Gene Regulation. Combinatorial Chemistry and High Throughput Screening, 2008, 11, 146-158.	1.1	17
52	Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor <i>mammary serine protease inhibitor</i>. Molecular Cancer Therapeutics, 2008, 7, 1080-1090.	4.1	58
53	Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene, 2007, 26, 2791-2798.	5.9	87
54	Interrogating Genomes with Combinatorial Artificial Transcription Factor Libraries: Asking Zinc Finger Questions. Assay and Drug Development Technologies, 2006, 4, 317-331.	1.2	20

#	Article	IF	Citations
55	Development of Zinc Finger Domains for Recognition of the 5â€²-CNN-3â€² Family DNA Sequences and Their Use in the Construction of Artificial Transcription Factors. Journal of Biological Chemistry, 2005, 280, 35588-35597.	3.4	166
56	Genetic reprogramming of tumor cells by zinc finger transcription factors. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 11716-11721.	7.1	44
57	Designing Transcription Factor Architectures for Drug Discovery. Molecular Pharmacology, 2004, 66, 1361-1371.	2.3	162
58	Promoter-targeted Phage Display Selections with Preassembled Synthetic Zinc Finger Libraries for Endogenous Gene Regulation. Journal of Molecular Biology, 2004, 340, 599-599.	4.2	0
59	Promoter-targeted Phage Display Selections with Preassembled Synthetic Zinc Finger Libraries for Endogenous Gene Regulation. Journal of Molecular Biology, 2004, 340, 599-613.	4.2	26
60	In Vivo Selection of Combinatorial Libraries and Designed Affinity Maturation of Polydactyl Zinc Finger Transcription Factors for ICAM-1 Provides New Insights into Gene Regulation. Journal of Molecular Biology, 2004, 341, 635-649.	4.2	49
61	Scanning the human genome with combinatorial transcription factor libraries. Nature Biotechnology, 2003, 21, 269-274.	17.5	120
62	Evaluation of a Modular Strategy for the Construction of Novel Polydactyl Zinc Finger DNA-Binding Proteinsâ€. Biochemistry, 2003, 42, 2137-2148.	2.5	161
63	The recognition of a noncanonical RNA base pair by a zinc finger protein. Chemistry and Biology, 1999, 6, 585-597.	6.0	17
64	PolI-driven integrative expression vectors for yeast. Journal of Biotechnology, 1997, 56, 41-47.	3.8	1